Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma

Zhou,Changxin; Li,Jinbo; Wang,Yu; Xue,Shoukun; Zhang,Yang

doi:10.3892/ol.2018.9572

Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma

Authors:
- Changxin Zhou
- Jinbo Li
- Yu Wang
- Shoukun Xue
- Yang Zhang
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of General Surgery, Gaotang County People's Hospital, Liaocheng, Shandong 252800, P.R. China, Department of Thoracic Surgery, Liaocheng Tumor Hospital, Liaocheng, Shandong 252800, P.R. China
Published online on: October 12, 2018 https://doi.org/10.3892/ol.2018.9572
Pages: 183-194
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Differences in BRAF gene mutation frequency and thyroid-stimulating hormone receptor (TSHR) protein expression in thyroid tissues were detected to investigate their association with local tissue invasion and cervical lymph node metastasis potential of papillary thyroid microcarcinoma (PTMC). The BRAF gene mutation frequency and TSHR expression in PTMC patients were detected via qPCR and immunohistochemical method, and the association between them was discussed combined with the clinical and pathological parameters. Kruskal-Wallis test was used for the univariate correlation analyses and comparison of mutation rate and expression rate, and Chi-square test was used for the association of central lymph node metastasis with BRAF gene and TSHR. The BRAFV600E mutation only existed in patients with thyroid cancer. Τhe larger the number of metastatic central lymph nodes was, the higher the proportion of BRAFV600E mutation would be. Τhe BRAFV600E mutation was related to the primary lesion size, capsular infiltration and lymph node metastasis of PTMC (P<0.05). The expression of TSHR in PTMC tissues was < those in thyroid benign lesions and para-carcinoma normal tissues, which was positively associated with the central lymph node metastasis (P<0.05). Τhe low expression of TSHR was related to the primary lesion size, capsular infiltration and metastatic lymph nodes of PTMC (P<0.05). The BRAFV600E and TSHR may be involved in the occurrence and lymphatic metastasis of PTMC. The BRAFV600E mutation has no association with the TSHR protein expression (P=0.256), but the coincidence coefficient indicates that their diagnostic significance in PTMC is not similar, so BRAFV600E mutation and TSHR protein expression can be used jointly in the prediction of invasion and lymph node metastasis of PTMC, which may be more meaningful for clinical guidance.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Cox AE and LeBeau SO: Diagnosis and treatment of differentiated thyroid carcinoma. Radiol Clin North Am. 49:453–462. 2011. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
4	Cao Y, Xia J, Li Y, Wang L and Jiang Z: Study on the effect of salt plus iodine on the hospitalization of thyroid diseases in a hospital. Chin J Health Stat. 29:236–242. 2012.(In Chinese).
5	Zhao H, Jiang W, Guan F, Hou F and Cheng H: Application of ¹³¹I in the study of residual thyroid tissue dose after differentiated thyroid cancer. J Jilin Univ (Med Ed). 35:191–194. 2009.(In Chinese).
6	Sciuto R, Romano L, Rea S, Marandino F, Sperduti I and Maini CL: Natural history and clinical outcome of differentiated thyroid carcinoma: A retrospective analysis of 1503 patients treated at a single institution. Ann Oncol. 20:1728–1735. 2009. View Article : Google Scholar : PubMed/NCBI
7	Choi YM, Kim TY, Song DE, Hong SJ, Jang EK, Jeon MJ, Han JM, Kim WG, Shong YK and Kim WB: Papillary thyroid carcinoma arising from a thyroglossal duct cyst: A single institution experience. Endocr J. 60:665–670. 2013. View Article : Google Scholar : PubMed/NCBI
8	Vergamini LB, Frazier AL, Abrantes FL, Ribeiro KB and Rodriguez-Galindo C: Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: A population-based study. J Pediatr. 164:1481–1485. 2014. View Article : Google Scholar : PubMed/NCBI
9	Londero SC, Krogdahl A, Bastholt L, Overgaard J, Pedersen HB, Frisch T, Bentzen J, Pedersen PU, Christiansen P and Godballe C: Papillary thyroid carcinoma in Denmark 1996-2008: An investigation of changes in incidence. Cancer Epidemiol. 37:e1–e6. 2013. View Article : Google Scholar : PubMed/NCBI
10	Radespiel-Tröger M, Batzler WU, Holleczek B, Luttmann S, Pritzkuleit R, Stabenow R, Urbschat I, Zeissig SR and Meyer M; Im Namen der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V, . Rising incidence of papillary thyroid carcinoma in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 57:84–92. 2014.(In German). View Article : Google Scholar : PubMed/NCBI
11	Joshi P, Nair S, Nair D and Chaturvedi P: Incidence of occult papillary carcinoma of thyroid in Indian population: Case series and review of literature. J Cancer Res Ther. 10:693–695. 2014.PubMed/NCBI
12	Wu LS and Milan SA: Management of microcarcinomas (papillary and medullary) of the thyroid. Curr Opin Oncol. 25:27–32. 2013. View Article : Google Scholar : PubMed/NCBI
13	Moosa M and Mazzaferri EL: Occult thyroid carcinoma. Cancer. 10:180–188. 1997.
14	Pacini F: Thyroid microcarcinoma. Best Pract Res Clin Endocrinol Metab. 26:421–429. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kim NH, Beak SK, Baik SH, Choi DS and Kim SG: A patient with micropapillary thyroid carcinoma and macronodular lung metastasis: Stable disease for eight years without treatment. Thyroid. 19:309–311. 2009. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Cui Z, Sun S, Ren Y, Xu J, Yao Y, Chen Q, Zhang W, Li R, Guan Z, et al: Study on the significance and method of cervical lymph node dissection in differentiated thyroid carcinoma. Chin J Pract Surg. 31:414–416. 2011.(In Chinese).
17	Robinson MJ and Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 9:180–186. 1997. View Article : Google Scholar : PubMed/NCBI
18	MacCorkle RA and Tan TH: Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys. 43:451–461. 2005. View Article : Google Scholar : PubMed/NCBI
19	Zhang BH and Guan KL: Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19:5429–5439. 2000. View Article : Google Scholar : PubMed/NCBI
20	Tufano RP, Teixeira GV, Bishop J, Carson KA and Xing M: BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: A systematic review and meta-analysis. Medicine (Baltimore). 91:274–286. 2012. View Article : Google Scholar : PubMed/NCBI
21	Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 309:1493–1501. 2013. View Article : Google Scholar : PubMed/NCBI
22	Chen W, Yin D, Lu X and Qiu X: Expression and significance of TSHR ER and CyclinD1 in differentiated thyroid carcinoma. J Zhengzhou Univ (Med Sci). 5:3542005.(In Chinese).
23	Shi Y, Zou M and Farid NR: Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis. Clin Endocrinol (Oxf). 39:269–274. 1993. View Article : Google Scholar : PubMed/NCBI
24	Tanaka K, Inoue H, Miki H, Masuda E, Kitaichi M, Komaki K, Uyama T and Monden Y: Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: Immunohistochemical detection of TSH-R. Br J Cancer. 76:594–599. 1997. View Article : Google Scholar : PubMed/NCBI
25	Liu X and Gao M: The relationship between the anti-oxidative conduction pathway of thyroxine and the invasion force of thyroid papillary carcinoma. Chin J Otorhinolaryngol Head Neck Surg. 44:287–291. 2009.(In Chinese).
26	Shi C, Qin H, Ding C, Sun Y, Lyu Y and Shi T: Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma. Zhonghua Zhong Liu Za Zhi. 37:123–127. 2015.(In Chinese). PubMed/NCBI
27	Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, et al: Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab. 101:264–274. 2016. View Article : Google Scholar : PubMed/NCBI
28	Stewart BW and Kleihues P: World Cancer Report. IARC Press; Lyon: 2003
29	Kim HJ, Kim NK, Choi JH and Kim SW, Jin SM, Suh S, Bae JC, Min YK, Chung JH and Kim SW: Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 78:614–620. 2013. View Article : Google Scholar : PubMed/NCBI
30	Lee KJ, Cho YJ, Kim JG and Lee DH: How many contralateral papillary thyroid carcinomas can be missed? World J Surg. 37:780–785. 2013. View Article : Google Scholar : PubMed/NCBI
31	Davies L and Welch HG: Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
32	Pedrazzini L, Baroli A, Marzoli L, Guglielmi R and Papini E: Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up. Minerva Endocrinol. 38:269–279. 2013.PubMed/NCBI
33	Liu T and Qi J: Diagnosis and surgical treatment of differentiated thyroid carcinoma. Int J Endocrinol. 26:344–346. 2006.
34	Chung YJ, Lee JS, Park SY, Park HJ, Cho BY, Park SJ, Lee SY, Kang KH and Ryu HS: Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma. Histopathology. 62:578–588. 2013. View Article : Google Scholar : PubMed/NCBI
35	Bruno R, Giannasio P, Chiarella R, Capula C, Russo D, Filetti S and Costante G: Identification of a neck lump as a lymph node metastasis from an occult contralateral papillary microcarcinoma of the thyroid: Key role of thyroglobulin assay in the fine-needle aspirate. Thyroid. 19:531–533. 2009. View Article : Google Scholar : PubMed/NCBI
36	Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS and Carrasco N: The sodium/iodide symporter: Characterization, regulation, and medical significance. Endorcrine Rev. 24:48–77. 2003. View Article : Google Scholar
37	Ikawa S, Fukui M, Ueyama Y, Tamaoki N, Yamamoto T and Toyoshima K: B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol. 8:2651–2654. 1988. View Article : Google Scholar : PubMed/NCBI
38	Ji Y and Xie N: Clinical study of BRAF gene mutation in thyroid papillary carcinoma. Guangdong Med J. 30:1183–1185. 2009.(In Chinese).
39	Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S and Hemminki K: BRAF mutations in metastatic melanoma: A possible association with clinical outcome. Clin Cancer Res. 9:3362–3368. 2003.PubMed/NCBI
40	Bansal M, Gandhi M, Ferris RL, Nikiforova MN, Yip L, Carty SE and Nikiforov YE: Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am J Surg Pathol. 37:1586–1591. 2013. View Article : Google Scholar : PubMed/NCBI
41	Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ and Nikiforov YE: The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 99:E276–E285. 2014. View Article : Google Scholar : PubMed/NCBI
42	Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ and Qu JM: The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 17:3294–3300. 2010. View Article : Google Scholar : PubMed/NCBI
43	Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo H and Youn YK: BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 36:310–317. 2012. View Article : Google Scholar : PubMed/NCBI
44	Kwak JY, Jeong JJ, Kang SW, Park S, Choi JR, Park SJ, Kim EK and Chung WY: Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas. Head Neck. 35:1630–1633. 2013. View Article : Google Scholar : PubMed/NCBI
45	Guan H, Guan H, Lu J, Rong S, Guo X and Li X: Meta-analysis of thyroid hormone level and thyroid cancer in Chinese population. J Environ Health. 30:1115–1116. 2013.(In Chinese).
46	Lu X, Ge M, Ling Z, Hu S, Xu Z, Zheng C, Tan Z and Chen C: Correlation and clinical significance of abnormal methylation of hMLH, NIS and TSHR in thyroid papillary carcinoma. Tumor. 33:445–453. 2013.(In Chinese).
47	Tonacchera M, Viacava P, Fanelli G, Agretti P, De Marco G, De Servi M, Di Cosmo C, Chiovato L, Pinchera A and Vitti P: The sodium-iodide symporter protein is always present at a low expression and confined to the cell membrane in nonfunctioning nonadenomatous nodules of toxic nodular goitre. Clin Endocrinol (Oxf). 61:40–45. 2004. View Article : Google Scholar : PubMed/NCBI
48	Smith JA, Fan CY, Zou C, Bodenner D and Kokoska MS: Methylation status of genes in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 133:1006–1011. 2007. View Article : Google Scholar : PubMed/NCBI
49	Li C, Lee KC, Schneider EB and Zeiger MA: BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: Meta-analysis A. J Clin Endocrinol Metab. 97:4559–4570. 2012. View Article : Google Scholar : PubMed/NCBI
50	Wang J, Wu G, Ma X, Liu Y, Chen H and Huang W: BRAF gene mutation and clinical significance in thyroid tumor tissue. Chin J Exp Surg. 28:1102–1104. 2011.(In Chinese).
51	Russo M, Malandrino P, Nicolosi ML, Manusia M, Marturano I, Trovato MA, Pellegriti G, Frasca F and Vigneri R: The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome. Thyroid. 24:1267–1274. 2014. View Article : Google Scholar : PubMed/NCBI
52	Wang W, Lu R, Dong Y and Liang J: V600E BRAF gene mutation and I-II papillary thyroid cancer clinical pathological characteristics and prognosis of correlation analysis. Linchuang Zhongliuxue Zazhi. 18:1100–1103. 2013.(In Chinese).
53	Min JJ, Chung JK, Lee Y, Jeong J, Lee D, Jang J, Lee M and Cho B: Relationship between expression of the sodium/iodide symporter and (l31)I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 28:639–645. 2001. View Article : Google Scholar